76 patents
Utility
Combination therapy with a glucagon receptor (GCGR) antibody and an anti-CD3 antibody
19 Dec 23
The present disclosure provides methods comprising a glucagon receptor antagonist in combination with an immunotherapeutic agent for treatment of disease.
Zhonghao Liu
Filed: 17 Feb 21
Utility
C3-BINDING Agents and Methods of Use Thereof
30 Nov 23
The present disclosure provides binding agents, such as antibodies (including single chain variable fragments), that specifically bind complement component C3, including human C3, compositions comprising same, and methods of their use.
Dana Yen Mei Duey, Zhonghao Liu, Jie Tang, Yan Wang, Yiyuan Yin, Wenwu Zhai, Jared Martin Higbee
Filed: 10 Aug 23
Utility
ILT-binding agents and methods of use thereof
31 Oct 23
The present disclosure provides binding agents, such as antibodies, that specifically bind ILT2, ILT4, or both ILT2 and ILT4, as well as compositions comprising the binding agents, and methods of their use.
Dana Yen Mei Duey, Allen James Ebens, Jr., Daniel David Kaplan, Chia-Ying Kao Lam, Kalyani Mondal, Geoffrey William Stone, Yan Wang
Filed: 29 Apr 21
Utility
Compositions and Methods of Use for Treating Metabolic Disorders
5 Oct 23
A complex comprising a GDF15 polypeptide is described.
Wenyan Shen, Darrin Anthony Lindhout, Raj Haldankar, Hugo Matern
Filed: 7 Nov 22
Utility
C3-binding agents and methods of use thereof
26 Sep 23
The present disclosure provides binding agents, such as antibodies (including single chain variable fragments), that specifically bind complement component C3, including human C3, compositions comprising same, and methods of their use.
Dana Yen Mei Duey, Zhonghao Liu, Jie Tang, Yan Wang, Yiyuan Yin, Wenwu Zhai, Jared Martin Higbee
Filed: 19 Aug 21
Utility
ILT3-binding agents and methods of use thereof
19 Sep 23
The present disclosure provides binding agents, such as antibodies, that specifically bind ILT3, including human ILT3, as well as compositions comprising the binding agents, and methods of their use.
Suzanne Christine Crawley, Jer-Yuan Hsu, Daniel David Kaplan, Betty Chan Li, Vicky Yi-Bing Lin, Seth Malmersjö, Kevin James Paavola, Julie Michelle Roda, Yan Wang
Filed: 17 Dec 20
Utility
Methods of reducing or lowering blood glucose levels in a human subject by administering an antibody that specifically binds human glucagon receptor
22 Aug 23
The present disclosure provides binding proteins, such as antibodies, that bind glucagon receptors, including a human glucagon receptor, and methods of their use.
Wenyan Shen, Yan Wang, Hugo Matern, Zhonghao Liu
Filed: 19 Mar 21
Utility
Binding Proteins and Methods of Use Thereof
17 Aug 23
The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.
Kalyani Mondal, Betty Chan Li, Yu Chen, Taruna Arora, Hugo Matern, Wenyan Shen
Filed: 12 Jan 23
Utility
Methods for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases
20 Jul 23
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Lei Ling, Jian Luo
Filed: 24 Jan 23
Utility
Combinational Use of an ANTI-ILT3 Antibody and an ANTI-LAIR-1 Antibody
13 Jul 23
The present disclosure provides combination therapies comprising the use of an antibody that binds human ILT3 and an antibody that binds human LAIR-1.
Varun Kapoor, Peirong Chen, Julie Michelle Roda
Filed: 20 Dec 22
Utility
Methods of Treating Cancer and Tumor-related Weight Loss and Cachexia
6 Apr 23
The present disclosure relates generally to methods of treating (i) a tumor (e.g., a solid tumor, an advanced solid tumor, a cancer), (ii) tumor-related weight loss, or (iii) tumor-related cachexia in a human patient, the method comprising administering to the human patient an anti-GDNF family receptor alpha-like (GFRAL) antibody, wherein the antibody inhibits GFRAL binding to Ret proto-oncogene (RET).
Daniel Chan, Alexander Mark DePaoli, Josh Lichtman, Bich Ngoc Tran-Muchowski, Yi Qun Xiao, Jiping Zha, Jian Luo
Filed: 2 Sep 22
Utility
Methods of treating nonalcoholic steatohepatitis comprising administering an anti-human beta klotho antibody or binding fragment thereof
7 Mar 23
The present disclosure provides binding proteins, such as antibodies and binding fragments thereof, that bind beta klotho, including human beta klotho, and methods of their use, including in the treatment of nonalcoholic steatohepatitis.
Kalyani Mondal, Betty Chan Li, Yu Chen, Taruna Arora, Hugo Matern, Wenyan Shen
Filed: 14 Jul 20
Utility
Methods of Treating Fibroblast Growth Factor 19-MEDIATED Cancers and Tumors
2 Feb 23
Provided are methods of treating a FGF19-mediated cancer or tumor in a subject by administering to the subject an anti-IL-6 antibody or an anti-IL-6 receptor antibody or an inhibitor of STAT3/JAK signaling pathway, and pharmaceutical compositions relating thereto.
Lei Ling, Hui Tian
Filed: 17 Jun 22
Utility
Methods of using compositions comprising variants of FGF19 polypeptides for treating primary biliary cirrhosis in a subject
31 Jan 23
The invention relates to methods of using variants of fibroblast growth factor 19 (FGF19) for treating primary biliary cirrhosis.
Lei Ling, Jian Luo
Filed: 13 Feb 18
Utility
Methods of lowering triglyceride levels with an ANGPTL8-binding antibody or antigen-binding fragment thereof
31 Jan 23
The present disclosure provides binding agents, such as antibodies, that specifically bind Angiopoietin-like protein 8 (ANGPTL8), including human ANGPTL8, and methods of their use.
Chun Chu, Xunshan Ding, Zhonghao Liu, Yan Wang, Yiyuan Yin, Wenwu Zhai
Filed: 18 Aug 20
Utility
Methods of treating a wasting syndrome, increasing growth hormone levels, and increasing GHSR activity with a LEAP2 antibody
10 Jan 23
The present disclosure provides binding agents that modulate the interaction between liver-expressed antimicrobial peptide 2 (LEAP2) and growth hormone secretagogue receptor (GHSR).
Daniel David Kaplan, Xuecai Ge, Hui Tian
Filed: 14 Aug 20
Utility
Compositions and methods of use for treating metabolic disorders
20 Dec 22
A complex comprising a GDF15 polypeptide is described.
Wenyan Shen, Darrin Anthony Lindhout, Raj Haldankar, Hugo Matern
Filed: 15 Jan 20
Utility
HTRA1-BINDING Agents and Methods of Use Thereof
11 Aug 22
The present disclosure provides binding agents, such as antibodies, that specifically bind HTRA1, including human HTRA1, as well as compositions comprising the binding agents, and methods of their use.
Chun Chu, Raj Haldankar, Betty Chan Li, Zhonghao Liu, Alexander V. Loklev, Jie Tang, Yan Wang
Filed: 7 Feb 22
Utility
Methods and Uses for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases
4 Aug 22
Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.
Lei LING, Hui TIAN
Filed: 27 Dec 21
Utility
Compositions and methods of use for treating metabolic disorders
14 Jun 22
Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
Darrin Anthony Lindhout, Raj Haldankar, Hui Tian, Jer-Yuan Hsu
Filed: 7 Feb 20